Last: | $1.365 |
---|---|
Change Percent: | 0.71% |
Open: | $1.4 |
Close: | $1.365 |
High: | $1.44 |
Low: | $1.315 |
Volume: | 263,686 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.365 | $1.4 | $1.365 | $1.44 | $1.315 | 263,686 | 04-26-2024 |
$1.41 | $1.42 | $1.41 | $1.42 | $1.3027 | 169,155 | 04-25-2024 |
$1.42 | $1.53 | $1.42 | $1.58 | $1.38 | 318,351 | 04-24-2024 |
$1.5 | $1.56 | $1.5 | $1.6 | $1.49 | 161,312 | 04-23-2024 |
$1.57 | $1.55 | $1.57 | $1.6 | $1.49 | 181,253 | 04-22-2024 |
$1.56 | $1.56 | $1.56 | $1.605 | $1.52 | 169,010 | 04-19-2024 |
$1.58 | $1.64 | $1.58 | $1.65 | $1.56 | 169,330 | 04-18-2024 |
$1.63 | $1.5 | $1.63 | $1.64 | $1.5 | 315,904 | 04-17-2024 |
$1.495 | $1.57 | $1.495 | $1.67 | $1.47 | 286,850 | 04-16-2024 |
$1.595 | $1.77 | $1.595 | $1.77 | $1.57 | 239,114 | 04-15-2024 |
$1.75 | $1.76 | $1.75 | $1.76 | $1.65 | 343,510 | 04-12-2024 |
$1.76 | $1.81 | $1.76 | $1.85 | $1.66 | 429,905 | 04-11-2024 |
$1.775 | $1.87 | $1.775 | $1.9 | $1.72 | 244,454 | 04-10-2024 |
$1.9 | $1.94 | $1.9 | $1.96 | $1.81 | 537,938 | 04-09-2024 |
$2.04 | $1.9 | $2.04 | $2.08 | $1.85 | 464,499 | 04-08-2024 |
$1.85 | $1.8 | $1.85 | $1.85 | $1.75 | 220,401 | 04-05-2024 |
$1.78 | $1.83 | $1.78 | $1.87 | $1.74 | 234,025 | 04-04-2024 |
$1.77 | $1.8 | $1.77 | $1.8371 | $1.735 | 277,037 | 04-03-2024 |
$1.82 | $1.88 | $1.82 | $1.95 | $1.78 | 236,003 | 04-02-2024 |
$1.9 | $1.93 | $1.9 | $1.94 | $1.81 | 188,415 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cue Biopharma Inc. Company Name:
CUE Stock Symbol:
NASDAQ Market:
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel clas...
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at...
2024-04-09 12:15:02 ET Oppenheimer analyst issues UNDERPERFORM recommendation for CUE on April 9, 2024 10:01AM ET. The previous analyst recommendation was Underperform. CUE was trading at $1.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...